Sector News

PharmStars announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” theme for its Fall 2023 Accelerator

July 2, 2023
Life sciences

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” Startups with a digital product or prototype in the theme area are invited to apply by July 10, 2023.

The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies.

PharmStars seeks to bridge the “pharma-startup gap” by helping pharmaceutical firms and startups overcome cultural and other barriers to create productive partnerships, leading to greater success and faster adoption of digital solutions that improve patient outcomes. PharmStars’ unique PharmaU program provides education and intensive, personalized mentoring to help startups work more effectively with pharma.

“PharmStars is a fast-track MBA in pharma,” said Spring 2022 accelerator graduate David van Zuydam, CEO of Head Diagnostics (Dublin, Ireland).

PharmStars’ members will have priority access to the startups that complete the accelerator program. The program will culminate with a private Showcase Event in Boston in November 2023, at which each startup will present to and meet one-on-one with PharmStars’ pharma member companies.

“Our members have selected and shaped this cohort’s focus on the opportunity to innovate around the patient-drug interface. They are eager to work with startups with innovation in drug delivery platforms, medication supply chain efficiency and sustainability, and medication management,” said Naomi Fried, PharmStars’ founder and CEO.

The Fall 2023 program will be PharmStars’ fifth cohort. Forty-seven digital health startups have successfully graduated from the program since it launched in June 2021. Startups of all sizes have benefited from the program.

“Despite having collaborated with pharma companies for years, PharmaU was tremendously valuable to dive deep into the science and business of drug development, and has reframed our perspective on where and how we can add value and impact pharma,” explained Zainab Doctor, Vice President of Product at nference (Cambridge, MA) and Fall 2022 graduate.

Fall 2022 cohort graduate Sameer Sontakey, CEO of Biostrap (Los Angeles, CA), said, “Graduating from PharmStars has opened the door for us to so many great opportunities and partnerships, and we’re looking forward to continuing to build upon what we learned during those ten weeks!”

Applications for the Fall 2023 accelerator program and additional details are available now on the PharmStars’ website. PharmStars is also currently accepting a limited number of additional pharma and biotech members for 2023. Membership information can be found here.

About PharmStars
PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the gap,” leading to greater success and faster patient adoption of “beyond the molecule” solutions.


comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach